NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs
Prof Philippe Ruszniewski - Paris Diderot University, Paris, France
NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs ( Prof Philippe Ruszniewski - Paris Diderot University, Paris, France )
27 Sep 2015
RADIANT-4: Results of international trial show promise in the treatment of neuro...
Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA
RADIANT-4: Results of international trial show promise in the treatment of neuroendocrine tumours ( Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA )
27 Sep 2015
Mid-gut NETs respond to targeted radionuclide therapy: NETTER-1 results
Prof Philippe Ruszniewski - Paris Diderot University, Paris, France
Mid-gut NETs respond to targeted radionuclide therapy: NETTER-1 results ( Prof Philippe Ruszniewski - Paris Diderot University, Paris, France )
27 Sep 2015
Everolimus for non-functional neuroendocrine tumours
Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA
Everolimus for non-functional neuroendocrine tumours ( Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA )
26 Sep 2015
Highlights of the p-medicine project
Highlights of the p-medicine project (  )
2 Sep 2015
The p-medicine project and ECRIN
Jacques Demotes - ECRIN
The p-medicine project and ECRIN ( Jacques Demotes - ECRIN )
2 Sep 2015
Investigational ER degrader safe, with early signs of antitumour activity agains...
Dr Maura Dickler - Memorial Sloan Kettering Cancer Center, New York, USA
Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer ( Dr Maura Dickler - Memorial Sloan Kettering Cancer Center, New York, USA )
1 May 2015
New approaches and new partnership models for biomarker based clinical research
Dr Denis Lacombe, EORTC, Brussels, Belgium
New approaches and new partnership models for biomarker based clinical research ( Dr Denis Lacombe, EORTC, Brussels, Belgium )
6 Jan 2015
Aims and successes of the 2nd EurocanPlatform project translational research cou...
Christina von Gertten, Karolinska Institutet, Stockholm, Sweden
Aims and successes of the 2nd EurocanPlatform project translational research course ( Christina von Gertten, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015
Epigenome deregulation in cancer
Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, Fran...
Epigenome deregulation in cancer ( Dr Zdenko Herceg, International Agency for Research on Cancer (IARC), Lyon, France )
6 Jan 2015
Immunotherapy of cancer: recent progress and future challenges
Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden
Immunotherapy of cancer: recent progress and future challenges ( Prof Rolf Kiessling, Karolinska Institutet, Stockholm, Sweden )
6 Jan 2015
Reasons to attend the EurocanPlatform translational research course 2015
Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany
Reasons to attend the EurocanPlatform translational research course 2015 ( Dr Wilfried Reichardt, University Medical Center Freiburg, Freiburg, Germany )
6 Jan 2015